Related Experiment Videos
Mechanistic properties of immunoglobulin somatic mutation
J E Ford1, M G McHeyzer-Williams, M R Lieber
1Department of Pathology, Stanford University School of Medicine 94305-5324, USA.
Annals of the New York Academy of Sciences
|September 29, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Reconfigurable array interconnection by photorefractive correlation.
Applied optics·2010
Spatial Coherence Structure-Mediated Transmission of Encrypted Three-Dimensional Objects and Hidden Information.
Annals of the New York Academy of Sciences·2026
A Graph Network-Based Real-Time Precise Predicting Model for Progressive Collapse of Steel Frame Structures.
Annals of the New York Academy of Sciences·2026
Protégé Effect for Behavior Change: Does Teaching Digital Stress Solutions to Others Reduce One's Own?
Annals of the New York Academy of Sciences·2026
Early Ocular Response to Visual Motion in Patients With Persistent Postural-Perceptual Dizziness.
Annals of the New York Academy of Sciences·2026
Pain Expectation in Individuals With High Autistic Traits: Decision-Evaluation Processes and Oxytocin Modulation.
Annals of the New York Academy of Sciences·2026
Design of an Adaptive Model for Intelligent Car Seats Based on Human Pose Recognition.
Annals of the New York Academy of Sciences·2026
Lung biopsy strategies for childhood interstitial lung disease: Indications and techniques.
The Journal of international medical research·2026
"I know how important it is": A qualitative analysis of participants' experiences in a vaccine safety study.
Human vaccines & immunotherapeutics·2026
Evolution and Mechanistic Insights of Immunometabolism in Metabolic Diseases and Infections.
Scandinavian journal of immunology·2026
Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.
Rheumatology (Oxford, England)·2026
Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.
Cancer chemotherapy and pharmacology·2026